SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-044637
Filing Date
2021-08-16
Accepted
2021-08-16 16:16:02
Documents
52
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-10q_20210630.htm   iXBRL 10-Q 1253173
2 EX-31.1 ikt-ex311_6.htm EX-31.1 10202
3 EX-31.2 ikt-ex312_7.htm EX-31.2 10225
4 EX-32.1 ikt-ex321_9.htm EX-32.1 8834
5 EX-32.2 ikt-ex322_8.htm EX-32.2 8718
  Complete submission text file 0001564590-21-044637.txt   3897337

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ikt-20210630.xsd EX-101.SCH 33908
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ikt-20210630_cal.xml EX-101.CAL 29306
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ikt-20210630_def.xml EX-101.DEF 78628
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20210630_lab.xml EX-101.LAB 245043
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20210630_pre.xml EX-101.PRE 181363
11 EXTRACTED XBRL INSTANCE DOCUMENT ikt-10q_20210630_htm.xml XML 455108
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 211178395
SIC: 2836 Biological Products, (No Diagnostic Substances)